Intelliject, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted tentative approval for the company's New Drug Application (NDA) for a novel epinephrine auto-injector, e-cue™, for emergency treatment of allergic reactions including anaphylaxis. The tentative approval of e-cue™ following a first cycle, 10-month review by the FDA provides validation of Intelliject's vision of developing patient-centric products and of the company's ability to execute...
More...
More...